CEL-SCI TO PRESENT AT SOURCE CAPITAL GROUP'S 2016 DISRUPTIVE GROWTH & HEALTHCARE CONFERENCE

Vienna, VA, February 8, 2016 -- CEL-SCI Corporation (NYSE MKT: CVM) announced today that Geert Kersten, Chief Executive officer, will provide a company overview at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Wednesday, February 10, 2016 at 1:00 p.m. in New York City. For more information on the conference or for investors to register, please go to www.SourceCapitalConference.com.

About Source Capital Group

Source Capital Group, Inc. was founded in 1992 on the belief that the best investment advice should be independent, unbiased and tailor-made for the individual client's needs. Source Capital began as a boutique investment banking firm specializing in small to medium sized transactions. We have grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, in addition to our investment banking activity. http://www.sourcegrp.com/

About CEL-SCI Corporation

CEL-SCI is a Phase 3 immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. We believe that one must activate the immune system BEFORE radiation and chemotherapy, and even before surgery, to achieve the best results in the greatest number of patients. CEL-SCI is conducting a Phase 3 trial in 24 countries of Multikine (Leukocyte Interleukin Injection) for the treatment of head and neck cancer, which accounts for about 6% of cancers globally and a $6 billion market. Almost 700 patients are already enrolled in this study. CEL-SCI is also testing Multikine with the U.S. Navy in HIV infected patients with HPV related diseases. CEL-SCI has development partnerships with Teva Pharmaceuticals, Orient EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its own 75,000 sq. ft. manufacturing facility and produces Multikine for its clinical trials. When fully built out, this facility will have the capacity to supply about $3 billion worth of Multikine annually. CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology as a potential vaccine for the treatment of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.